MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Arcus Biosciences ROCE Ratio 2011-2026 | RCUS
Annual ROCE Ratio Arcus Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -61.17 | -68.04 | -73.59 | -42.62 | 6.41 | -24.7 | -49.17 | -21.26 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.41 | -73.59 | -41.77 |
Quarterly ROCE Ratio Arcus Biosciences
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -61.6 | -76.84 | -37.54 | -52.92 | -49.73 | -47.7 | -44.38 | -54.4 | -49.03 | -43.6 | -27.66 | -42.06 | -46.44 | -49.8 | -37.94 | -37.63 | -22.92 | -19.36 | -14.38 | -28.57 | -43.07 | -51.83 | -43.45 | -48.61 | -39.59 | -28.56 | -17.61 | 14.37 | 51.53 | 71.66 | 55.44 | 55.44 | 23.45 | 10.09 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 71.66 | -76.84 | -24.57 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Heron Therapeutics
HRTX
|
-17.71 | $ 0.79 | 1.9 % | $ 132 M |  USA |
 |
Altimmune
ALT
|
-42.02 | $ 3.44 | 2.99 % | $ 303 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Ascendis Pharma A/S
ASND
|
-45.89 | $ 218.03 | -1.74 % | $ 5 B |  Danmark |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-180.78 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-119.71 | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M | Canada |
 |
Incyte Corporation
INCY
|
29.32 | $ 90.43 | -0.21 % | $ 17.7 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Inovio Pharmaceuticals
INO
|
-122.66 | $ 1.54 | -2.41 % | $ 34.1 M | USA |
 |
Avenue Therapeutics
ATXI
|
-403.4 | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
-59.12 | $ 13.57 | 7.1 % | $ 818 M | USA |
 |
Atreca
BCEL
|
-34.9 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Inventiva S.A.
IVA
|
-23.77 | $ 6.07 | 4.97 % | $ 138 M | France |
 |
Calithera Biosciences
CALA
|
-1377.15 | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
-212.83 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-45.41 | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-883.35 | - | -74.18 % | $ 955 K | USA |
 |
KalVista Pharmaceuticals
KALV
|
-91.44 | $ 16.82 | -1.06 % | $ 835 M | Britain |
 |
Checkpoint Therapeutics
CKPT
|
444.94 | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
80.97 | - | -7.23 % | $ 13 M | USA |
 |
Kamada Ltd.
KMDA
|
10.36 | $ 8.27 | 0.24 % | $ 260 M | Israel |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
23.38 | $ 2.13 | 1.67 % | $ 199 M | Israel |
 |
Karyopharm Therapeutics
KPTI
|
64.21 | $ 7.11 | -6.82 % | $ 866 K | USA |
 |
Denali Therapeutics
DNLI
|
-39.63 | $ 20.99 | 4.07 % | $ 3.45 B | USA |
 |
Keros Therapeutics
KROS
|
22.29 | $ 11.16 | 1.82 % | $ 415 M | USA |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-73.67 | $ 4.35 | 2.48 % | $ 722 M | Canada |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
-28.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
552.16 | - | -5.98 % | $ 34.1 M | USA |